Daily Sepsis Research Analysis
Three impactful sepsis studies emerged: a mechanistically innovative preclinical therapy using E. coli–derived carbon dots that co-silence innate immune pathways; an RCT biomarker sub-study (LOVIT) showing no benefit and possible heterogeneity of harm with intravenous vitamin C across sepsis subtypes; and a large prospective multicenter cohort demonstrating that left ventricular diastolic dysfunction is common in septic shock but not associated with 28-day mortality.
Summary
Three impactful sepsis studies emerged: a mechanistically innovative preclinical therapy using E. coli–derived carbon dots that co-silence innate immune pathways; an RCT biomarker sub-study (LOVIT) showing no benefit and possible heterogeneity of harm with intravenous vitamin C across sepsis subtypes; and a large prospective multicenter cohort demonstrating that left ventricular diastolic dysfunction is common in septic shock but not associated with 28-day mortality.
Research Themes
- Nano-immunomodulation and host–pathogen interface in sepsis therapy
- Biologic heterogeneity and treatment effect modification in sepsis
- Cardiac phenotyping and prognostication in septic shock
Selected Articles
1. Suppression of Sepsis Cytokine Storm by Escherichia Coli Cell Wall-Derived Carbon Dots.
E. coli cell wall–derived carbon dots (E-CDs) attenuated inflammatory cytokine production, preserved organ function, and improved survival in septic mice. Mechanistically, E-CDs competitively bound LBP–LPS, promoted lysosomal degradation of TLR4, suppressed NF-κB signaling, and reduced oxidative stress and mtDNA release to dampen the STING pathway. In septic cynomolgus monkeys and patient PBMCs, E-CDs also reduced inflammation and oxidative stress.
Impact: Introduces a first-in-class concept of converting pathogens into therapeutic carbon dots that co-silence innate immune pathways in sepsis, demonstrated across species including non-human primates.
Clinical Implications: While preclinical, this platform suggests a novel immunomodulatory therapy for cytokine storm in sepsis, potentially complementing antibiotics by targeting LPS–TLR4 signaling and oxidative stress pathways.
Key Findings
- E-CDs reduced inflammatory cytokine production, preserved organ functions, and improved survival in septic mice.
- E-CDs competitively bound to LBP with LPS, promoted lysosomal degradation of TLR4, and inhibited NF-κB activation.
- Antioxidant properties of E-CDs reduced oxidative stress and mitochondrial DNA release, suppressing STING pathway overactivation.
- E-CDs alleviated inflammation and oxidative stress in septic cynomolgus monkeys and human patient PBMCs.
Methodological Strengths
- Cross-species validation (mice, cynomolgus monkeys, and human PBMCs) with convergent mechanistic evidence.
- Clear molecular mechanisms demonstrated (LBP–LPS competition, TLR4 lysosomal degradation, NF-κB/STING pathway modulation).
Limitations
- Preclinical evidence; no human in vivo efficacy or safety data.
- Manufacturing, scalability, biodistribution, and immunogenicity profiles of E-CDs require rigorous evaluation.
Future Directions: Define pharmacokinetics/toxicology and dose–response in large animals, optimize manufacturing under GMP, and design early-phase clinical trials in high-risk sepsis populations.
Sepsis is a life-threatening disease caused by a dysregulated immune response to infection, often involving the translocation of Gram-negative bacteria such as Escherichia coli (E. coli) into the bloodstream, triggering a cytokine storm. Despite its severity, no effective drugs currently exist for sepsis treatment. This study explores whether pathogen-derived carbon dots can mitigate their inherent toxicity while leveraging their structural similarity to pathogens to competitively bind pattern recognition receptors, thereby inhibiting sepsis. Based on this concept, E. coli wall-derived carbo
2. Sepsis subtypes and differential treatment response to vitamin C: biological sub-study of the LOVIT trial.
In 457 LOVIT participants with biomarker data, three inflammatory sepsis subtypes were identified. Intravenous vitamin C did not show anti-inflammatory effects across subtypes; time since randomization and concomitant hydrocortisone, not vitamin C, related to anti-inflammatory changes. Treatment effects trended toward harm in all subtypes with significant heterogeneity in magnitude (heterogeneity p=0.002).
Impact: Provides subtype-specific evidence that vitamin C is not beneficial in sepsis and may be harmful, reinforcing precision medicine approaches and informing de-implementation.
Clinical Implications: Routine intravenous vitamin C for sepsis should be avoided; biomarker-defined subtypes did not identify a benefiting group. Focus should shift to targeted therapies and robust phenotyping.
Key Findings
- Three inflammatory sepsis subtypes were identified using hierarchical clustering of biomarker profiles.
- Vitamin C showed no discernible anti-inflammatory effects; changes were associated with time and hydrocortisone, not vitamin C.
- Treatment effects favored harm across subtypes with significant heterogeneity in magnitude (heterogeneity p=0.002; ORs ~1.04, 1.33, 1.95).
Methodological Strengths
- RCT-embedded biomarker study with longitudinal sampling (baseline and day 7).
- Unsupervised clustering to define biologically coherent subtypes and formal heterogeneity testing.
Limitations
- Sub-study included 53% of trial participants with available plasma; potential selection bias.
- Not powered for definitive subgroup treatment-effect interactions on clinical endpoints.
Future Directions: Integrate multi-omics phenotypes with adaptive trial designs to match therapies to endotypes; prioritize therapies with biological plausibility in defined subtypes.
PURPOSE: We hypothesised that the biological heterogeneity of sepsis may highlight sepsis subtypes with differences in response to intravenous vitamin C treatment in the Lessening Organ Dysfunction with VITamin C (LOVIT) trial. Our aims were to identify sepsis subtypes and to test whether sepsis subtypes have differences in treatment effect to vitamin C and describe putative biological effects of vitamin C treatment. METHODS: We measured biomarkers of inflammation, at baseline and at 7 days post-randomisation, in 457/863 (53.0%) of participants with plasma samples in the LOVIT trial. We used agglomerative hierarchical clustering on log
3. Left ventricular diastolic dysfunction is prevalent but not associated with mortality in patients with septic shock.
In a prospective multicenter cohort of 402 septic shock patients, LV diastolic dysfunction (LVDD) was observed in 76% within the first 3 days but was not associated with 28-day mortality (adjusted ORs ~0.84–0.89; non-significant). Approximately one-third of survivors showed improvement or regression of LVDD over time.
Impact: Provides a high-quality negative result that challenges the prognostic utility of LV diastolic dysfunction in septic shock using contemporary echo criteria.
Clinical Implications: Routine reliance on LV diastolic dysfunction to risk-stratify septic shock mortality is not supported; management should remain guided by global severity and clinical response rather than LVDD status alone.
Key Findings
- LVDD detected in 76% of septic shock patients within first 3 ICU days.
- No association between LVDD and 28-day mortality (26% vs 28%; OR 0.90, p=0.696), consistent after adjustment for SAPS II/SOFA and fluid balance.
- About one-third of survivors showed improvement or regression of LVDD over time.
Methodological Strengths
- Prospective, multicenter design with repeated echocardiography using 2016 American–European guidelines.
- Adjusted analyses accounting for illness severity and fluid balance.
Limitations
- Follow-up echocardiography data available in 43% for later timepoints, potentially limiting longitudinal inference.
- Observational design cannot exclude residual confounding.
Future Directions: Investigate mechanistic links between transient myocardial dysfunction and outcomes, and evaluate whether LVDD-guided hemodynamic strategies improve patient-centered endpoints.
PURPOSE: Prognostic impact of left ventricular diastolic dysfunction (LVDD) in septic shock patients has not been determined using current diagnostic guidelines. We assessed the relation between LVDD during the first 3 days following intensive care unit (ICU) admission for septic shock and Day-28 mortality. METHODS: This prospective, multicenter, observational study enrolled 402 patients (age: 63 ± 13 year; 59% male; SAPS II: 59 ± 20; SOFA: 9.4 ± 3.6; mechanical ventilation: 74%) with septic shock (Sepsis-3 definition). Patients were echocardiographically assessed within 12 h after admission (Day 1), on Day 2, Day 3, at ICU and at hospital discharge (or Day 28 whichever occurred first), using 2016 American-European guidelines. RESULTS: LVDD was present at least once between Day 1 and 3 in 304 patients (76%), and in 56% and 44% of patients at ICU discharge and on Day 28 (or hospital discharge), respectively (43% of patients with follow-up). Seventy-eight of 172 patients (45%) exhibited similar LV diastolic properties throughout the study period while 58 patients (34%) improved their LVDD at follow-up (lower grade: n = 9, regression: n = 49). Day-28 mortality was not statistically different between patients with and without LVDD (80/304 [26%] vs. 25/88 [28%]; OR: 0.900 [0.530-1.527]; p = 0.696). Similar results were obtained when adjusting the multivariate model on SAPSII or SOFA score on admission, together with fluid balance during the first three days of ICU stay (OR: 0.838 [0.471-1.491]: p = 0.547 and OR: 0.887 [0.513-1.534]: p = 0.668, respectively). CONCLUSION: LVDD was highly prevalent in patients with septic shock but not associated with mortality. It appeared improving in one-third of survivors. TRIAL REGISTRATION: PRODIASYS study registered on ClinicalTrials (September 27, 2016, number NCT02918214).